



Development and current insights related to vaccines

“Learn from the past, act in the present and prepare for the future”

VACCINOLOGY
MASTER CLASS



Een programma voor zorgprofessionals in de infectiebestrijding

Een 2-daagse Vaccinology Masterclass 1 en 2 oktober 2020 in Almere. Het programma geeft een overzicht van de wetenschappelijke stand van zaken op het gebied van de ontwikkeling van vaccins en de toepassing ervan met een focus op het belang van de mucosale afweer, de mogelijk ongewenste effecten van vaccineren, de toepassing van vaccins in ontwikkelingslanden en de ontwikkeling van nieuwe vaccins voor respiratoire virussen. Uiteraard is er ook uitgebreid aandacht voor de laatste ontwikkelingen en inzichten omtrent COVID-19.

Datum: donderdag 1 en vrijdag 2 oktober 2020
Ontvangst donderdag vanaf 8.30 uur.

Locatie

Van der Valk hotel, Veluwezoom 45 Almere. Dichtbij de A6 en goed bereikbaar per openbaar vervoer.

Online

Online deelname is eveneens mogelijk. Beide dagen worden live gestreamd met een chatfunctie voor interactieve deelname. (Meer info zie ook bij inschrijving)


Programma

De inhoud van het programma is samengesteld door de Faculty van de Stichting Vaccinology Masterclass onder voorzitterschap van prof. dr. Ronald de Groot, kinderarts-infectioloog/immunoloog, Radboud UMC, Nijmegen.

Accreditatie aangevraagd voor 12 punten

Doelgroepen

Kinderartsen, internisten, infectiologen, medisch microbiologen, artsen infectieziekten, immunologen, jeugdartsen, gerieters, apothekers en overige geïnteresseerden.



Introductie:

De Stichting Vaccinology Masterclass organiseert elk jaar een twee daagse nascholing voor specialisten in het veld van de infectieziekten, microbiologie en immunologie. De afgelopen maanden is de wereld onomkeerbaar veranderd door de COVID-19 pandemie. Hierbij is het voor iedereen duidelijk geworden dat inzicht in het ontstaan en de verspreiding van nieuwe infectieziekten, snel-diagnostiek, optimale behandeling en preventie essentieel zijn voor de borging van de volksgezondheid. Kennis van reeds bekende infectieziekten en de wijze waarop deze kunnen worden voorkomen vormt de basis voor een op wetenschappelijke basis geschoeid effectief beleid.

In het programma van de tweedaagse van dit jaar komen verschillende aspecten van het vaccineren aan bod met een focus op het belang van de mucosale afweer, de mogelijk ongewenste effecten van vaccineren, toepassing van vaccins voor ontwikkelingslanden en de ontwikkeling van nieuwe vaccins voor respiratoire virussen. Uiteraard is er ook uitgebreid aandacht voor de laatste ontwikkelingen en inzichten omtrent COVID-19.

We kijken uit naar uw deelname aan deze energieke, interactieve en leerzame bijeenkomst.

Vriendelijke groet
Prof. dr. Ronald de Groot, voorzitter
Stichting Vaccinology Masterclass



Stichting Vaccinology Masterclass

De Stichting heeft twee doelen: ten eerste het bevorderen van onderwijs en opleiding op het gebied van vaccins en de toepassing daarvan; ten tweede het organiseren van cursussen, masterclasses en trainingen voor studenten en professionals werkzaam in de gezondheidszorg en het verrichten van al wat hiermee verband houdt of daartoe bevorderlijk kan zijn. De Stichting heeft geen winstoogmerk en heeft de ANBI status.

BESTUUR

- ✚ Prof. dr. Ronald de Groot, voorzitter
- ✚ Dr. Gerben Ferwerda, secretaris
- ✚ Dr. Nico Hartwig, penningmeester
- ✚ Mr. Cees Gips, bestuurslid
- ✚ Dr. Hans Rümke, bestuurslid

FACULTY LEDEN:

Prof. Dr. Ronald de Groot, kinderarts-infectioloog/immunoloog
dr. Nicoline van der Maas, arts Maatschappij en Gezondheid / epidemioloog
Dr. Hans Rümke, medisch vaccinoloog
Dr. Patricia Bruijning-Verhagen, kinderarts-epidemioloog
Dr. Gerben Ferwerda, internist-immunoloog/allergoloog
Prof. Dr. Maarten Postma, Global Health Economics en hoogleraar Pharmacoconomics
Drs. Henrike ter Horst, jeugdarts KNMG
Dr. Nico Hartwig, kinderarts-infectioloog
Dr. Wendy Unger, immunoloog
Drs. Marie José Sprakel, jeugdarts KNMG, Arts M&G
Dr. Roderick Venekamp, huisarts en universitair docent.


Ondersteunend congresburo:

Bruggink Communicatie Support
Gerhard Bruggink, directeur
Doraweg 3, 8531 PW Lemmer,
T 0514-533280/06-21424899
info@gerhardbruggink.nl




VACCINOLOGY MASTERCLASS

Program thursday 1 oktober 2020		
8.30 - 9.30	Inloop en registratie	
Mucosal immunology and vaccines		
09.30	General en current affair	Opening by the chairman Wendy Unger
9.40-10.20	Nils Lycke	Benefits of mucosal vaccination and the ability to protect against pandemic infections: <i>Current thinking and trends in mucosal vaccine development</i>
10.25-11.15	Martijn Nolte	Should I stay or should I go? <i>On the migration and maintenance of antigen-experienced T cells.</i>
11.15-11.40	Pause	
11.45-12.30	Debby Bogaert	The human microbiome and vaccination: <i>who affects whom?</i>
12.30-13.40	Lunch	
Vaccines: more than meets the eye		
13.40	Statements in advance	Opening by the chairman Henrike ter Horst
13.50-14.20	Gerben Ferwerda	Vaccination and allergies, is there an connection?
14.25-15.00	Martine Bakker	Aluminum in vaccines: <i>an additional risk for children?</i>
15.05-15.25	Pause	
15.30-16.10	Willem van Eden	Molecular mimicry in vaccination
16.15-16.55	Rik de Swart	The measles paradox: <i>how measles virus affects both the immuneseystem weakens as activates...</i>
17.00-17.30	Post-statement and discussion	Interactief o.l.v. Henrike ter Horst
17.30-18.00	Chat and drink	
18.00-18.15	Appetizer in the hall	Short introduction by Gerben Ferwerda
18.15-19.00	Rosanne Hertzberger	Don't become tone deaf: <i>How the citizen perspective is missing in the scientific discourse on vaccination.</i>
19.00	Main course and dessert in the restaurant	




VACCINOLOGY MASTERCLASS

Program friday 2 oktober 2020		
Developing vaccines for developing countries		
08.55	Nico Hartwig	Opening by the chairman
9.00-9.40	Helen McShane	Global progress in TB vaccine development
9.45-10.20	Matthijs Jore	Malaria vaccine: <i>are we almost there?</i>
10.25-10.45	Pause	
10.45-11.25	Erwin Duizer	New vaccines in the polio eradication endgame
11.30-12.00	Nathalie Macdermott	The race to the licensed Ebola vaccine: <i>guided by opportunity or science?</i>
12.00-13.20	Lunch	
Vaccination in the UK: current progress and experiences		
13.20	Patricia Bruijning Verhagen	Opening by the chairman
13.25-14.05	Harish Nair	RSV vaccination within reach?
14.10-14.50	Jaap van Dissel	State of play regarding Corona: the <i>Public Health perspectief</i>
15.00-15.20	Pause	
Keynote lecture		
15.20-16.10	Bart Haagmans	A novel coronavirus in China: <i>a story from the frontlines</i>
16.15-16.45	Closing with a drink	



Prof. Nils Lycke MD PhD

Professor of Clinical Immunology at the Sahlgrenska University Hospital Gothenburg Sweden. Professor Nils Lycke is the principal investigator of several internationally recognized projects focused on Mucosal Immunity and Tolerance where he is a leading researcher in the field. He has published over 180 original peer-reviewed papers and 35 reviews or book chapters. Lycke et. al. have pioneered the development of mucosal vaccines with important contributions to the field in adjuvant construction, including the patented CTA1-DD adjuvant. Basic mechanism of mucosal immune regulation, vaccine development and clinical assessment of safety & efficacy are other main research areas. He has been the coordinator of 6 EU-sponsored projects and has received financial support from EU, NIH, Wellcome Trust, Swedish Cancer foundation, Knut and Alice Wallenberg Foundation, The Swedish Strategic Research Foundation and the Swedish Research Council, and others. As a member of the WHO Transdisease Vaccinology Steering Committee for many years, Lycke has been deeply involved in vaccine design and development as well as interacting with industry and regulatory authorities. He has been an active contributor to many international and national conferences on the topic of mucosal immunity and tolerance. He has also organized several international meetings, including two Keystone symposia, The European Mucosal Immunology Group (he is also founder of EMIG), The International Mucosal Immunology Congress (SMI). The World Congress of Immunology (Stockholm), as well as being an invited speaker at congresses of national societies, such as the British, German, Italian and Irish immunology societies. Prof. Lycke has been a plenary speaker at various meetings including: EMIG in Prag 2006, ICMI in Tokyo 2007, EMIG in Milan 2008, Nobel forum on IBD 2008, European Immunology Congress Glasgow 2008, Berzelius Conference in Stockholm 2008, ICMI in Boston 2009, European Immunology Congress Berlin 2009, EMIG in Amsterdam 2010, EFSO Paris 2010, Adjuvants and Vaccines Dublin 2010, SSI Geilo 2011, ICMI Paris 2011, EFSO Spain 2011 and RIKEN IMS-RCAI/JSI International Symposium Yokohama, Japan 2013, ICMI in Berlin, Germany, 2016 and Brisbane, Australia in 2019. IUIS congress in Beijing, China in 2019. He is also an invited lecturer to many universities, including Scandinavian universities, the NIH and Pasteur Institute (Paris and Shanghai/China) and Imperial College (London).



Dr. Martijn A. Nolte

Principal Investigator at the Laboratory of Molecular Cell Biology Sanquin.

1997 - 2002 PhD at the Free University in Amsterdam

Department: Molecular Cell Biology, VU Medical Center

Promotor: Prof. Dr. Georg Kraal

Copromotor: Dr. Reina Mebius

Title of thesis: Compartments, Cells and Molecules in the Spleen.

2002 - 2004 Postdoctoral fellow at Academic Medical Center, Amsterdam

Department: Hematology / Experimental Immunology

Department head: Prof. Dr. Rien van Oers / Prof. Dr. Rene van Lier

Title research: The Function of CD27 on Hematopoietic Stem Cells.

2004 - 2006 Postdoctoral fellow at Cancer Research UK, London, United Kingdom

Department: Immunobiology Lab

Department head: Dr. Caetano Reis e Sousa

Title research: Dendritic Cells and their Environment.

2006 - 2010 Principal Investigator at Academic Medical Center, Amsterdam

Department: Experimental Immunology

Department head: Prof. Dr. Rene van Lier

Title research: The Influence of the Activated Immune System on Hematopoiesis.

2011 - 2018 Principal Investigator/Head of Laboratory at Sanquin Research, Amsterdam

Lab: Adaptive Immunity Lab

Department: Hematopoiesis

Department head: Dr. Marieke von Lindern

Title research: T cell Immunity and its Impact on Hematopoiesis.

2018 - current: Principal Investigator at Sanquin Research, Amsterdam

Lab: Lab of Molecular Cell Biology & Core Facility

Department: Molecular & Cellular Hemostasis

Department head: Prof. Dr. Sander Meijer

Research focus: Microscopy, Adaptive Immunity, Leukocyte migration



Prof. Debby Bogaert, MD, PhD

Chair of Paediatric Medicine, University of Edinburgh
Honorary consultant Royal Hospital for Sick Children
Center for Inflammation Research
The Queen's Medical Research Institute
Edinburgh BioQuarter
47 Little France Crescent
EH16 4TJ, Edinburgh

Prof. dr. Debby Bogaert joined the Centre for Inflammation Research in September 2016. She worked since 2008 as a physician scientist at the Department of Pediatric Immunology of the UMC Utrecht, The Netherlands. There she initiated several ecological studies of the upper respiratory tract microbiome in relation to pathogenesis and prevention of respiratory infections. A Veni and Vidi career grant (NWO) and Top grant (ZonMW) have led to the validation and adaptation of a metagenomic pipeline for analysis of low-density respiratory microbiota, the set-up of applied bio-informatic methods and the first analyses of environmental effects on such microbiota including mode of delivery, breastfeeding and outcome. Furthermore, she participates in and facilitates microbiological and immunological research projects linked to clinical studies. In the past she worked from 2006 to 2008 as a postdoctoral fellow (Professor M Lipsitch and Professor R Malley, Harvard School of Public Health/Boston Children's Hospital) where she executed in vitro and animal studies on susceptibility of infants to pneumococcal colonization and infection, with specific emphasis on host-immunity. She obtained her PhD degree cum laude from the Erasmus University in Rotterdam, Netherlands (Supervisors: Professor R de Groot, Professor P Hermans, 1999-2004), for her studies on pathogenesis of pneumococcal infections, focusing on (molecular) epidemiology of bacterial colonization of the upper respiratory tract. Amongst others, she was one of the first to obtain epidemiological evidence for in vivo bacterial interactions occurring at the nasopharyngeal niche.

In parallel, she was also trained as a pediatrician at the Sophia Children's Hospital in Rotterdam, obtaining her license in 2006. She obtained her licence as Paediatric Infectious Diseases and Immunology Specialist at the Wilhelmina Children's Hospital, Utrecht in 2014.


My research group has a major focus on investigating the physiology and pathophysiology of respiratory infections and inflammation from an ecological perspective, with the ultimate goal to design new or improved treatment and preventive measures for respiratory infections in susceptible populations. To this purpose, the team uses a fully translational approach, combining epidemiological, molecular microbiological, immunological and systems biology approaches to answer their research questions. Moreover, we execute mechanistic studies in vitro and in vivo. She still has a research team in Utrecht, the Netherlands, working on continuation of several birth cohorts and clinical studies.



Dr. Martine I. Bakker

Centrum voor Veiligheid van Stoffen en Producten
RIVM, Bilthoven
Tel. 030-274 3634
martine.bakker@rivm.nl

After finalizing the studies Chemistry and Environmental Sciences at Utrecht University, Martine Bakker wrote her PhD-thesis at the Research Institute for Toxicology (currently Institute of Risk Assessment Sciences) at the same university. From 2001 she has been working as a scientist and project coordinator at the Research Institute of Public Health and the Environment (RIVM) in Bilthoven. Her area of expertise ranges from modelling of exposure and risk of chemical substances in food and consumer products to management of research data with a focus on nanomaterials.




Dr. Gerben Ferwerda

Internist-researcher, studied medicine at the Faculty of Medicine of the VU University in Amsterdam (cum laude). He then continued his training as a doctor-researcher, a combination of Internal Medicine and PhD research, at the Radboud University Medical Center in Nijmegen. During this period, he also worked at the Sir William Dunn School of Pathology, Oxford University, UK. After completing his doctoral research on 'cross-talk of inflammatory pathways for pathogen recognition', he accepted a full-time position as a senior researcher at the Laboratory of Infectious Diseases (LKI) at the Radboud umc in 2009. At the LKI he leads the research into respiratory viral infections. The main focus of this group is (primary) serious respiratory infections in young children. The aim is to understand the innate immunological mechanisms underlying the development of a serious disease. For this purpose, a regional clinical network has been built and a biobank has been constructed with samples from young children (<12 months) with an acute low respiratory tract infection. Combining transcriptome analysis of leukocytes with functional immunoassays, inflammatory pathways involved in a serious disease course and potential new biomarkers have been identified. This research was conducted within the VIRGO consortium (www.virgo.com). Based on these findings, two research lines are currently underway:

1. The effect of maternal antibodies on the induction of the (innate) immune response during (primary) RSV infections in young children.

We are studying this in the context of the development of maternal vaccination.

2. The role of colonizing bacteria of the respiratory tract (microbiome) in the induction of the innate immune response during acute lower respiratory tract infection and its effect on the severity of the disease. Understanding this mucosal immune response during viral infections is being used to develop new diagnostic and prognostic tests.



VACCINOLOGY MASTERCLASS


Prof. Dr. W. van Eden, MD, PhD

Willem van Eden is an immunologist and medical microbiologist. After his promotion time in Leiden (promoter Jon J. van Rood), he won two prizes. In 1983 he received a prestigious Bruno Mendel fellowship from the English Royal Society. This allowed him to conduct research for two years in Israel (with Irun Cohen) at the renowned Weizmann Institute of Science in Rehovot. In 1984 he was elected winner of the Prix Zambon Benelux for his work in the field of infectious diseases pathology.

After returning from Israel, he attracted attention due to two simultaneous publications in the top medical journal Lancet. This prompted de Volkskrant to pay extensive attention to his work on the possible relationships between infectious and autoimmune diseases.

In 1988 it was discovered by van Eden and colleagues that stress proteins are fundamental for maintaining self-tolerance. Partly the result of serendipity. The publication in Nature was subsequently one of the 100 most cited publications in biomedical literature for two years. Building on this finding, Van Eden and his group are working on a vaccine against chronic inflammatory diseases based on heat shock proteins.

Van Eden is Scientific Director of the university spinn-off company Trajectum Pharma and coordinated four EU consortia. Van Eden's activities focus on both the veterinary and the human domain. Until recently he was a member of the health council (committee National Vaccination Program and the Standing Committee on Infection and Immunity) and is a member of EVAG, the standing committee on European vaccine policy, of the European Center for Disease Prevention and Control (ECDC).




Dr. Rik L. de Swart

Rik de Swart studied Biology in Utrecht (completed in 1990) and obtained a doctorate from Erasmus University Rotterdam in 1995. As a postgraduate researcher he studied the effectiveness of different candidate measles vaccines in a monkey model. He now works as an Associate Professor at the Viroscience department of Erasmus MC. His studies focus on pathogenesis of measles virus, respiratory syncytial virus and human metapneumovirus, with particular attention to interactions between these viruses and the immune system of the host. A recurring research theme is immunological identification correlates of protection or disease: respiratory virus infections often plays an active role in the disease process. Use is made of this from recombinant viruses expressing fluorescent reporter proteins, that infected cells both in vitro (in cell culture models) and in vivo (in animal models) can be demonstrated with high sensitivity. Be with this among others the main target cells of the measles virus during the onset of the infection, during spread within the host and upon transmission to the next host identified. In addition, a model was developed that can explain the measles paradox: the virus induces a strong measles specific immune response that leads to lifelong protection but ensures simultaneously for weakening the immune response to other infectious diseases. Rik de Swart 's research group showed that measles virus is preferentially the infects and depletes memory cells of the immune system, leading to "Immunological amnesia" (immune amnesia).

Recently supplemental evidence for this model was collected in an observational cohort study conducted during a measles outbreak among unvaccinated children in the Orthodox Protestant community. Also by the target cells of the live attenuated measles vaccine virus it was possible to clarify why measles vaccination does not causes immune suppression.

Rik de Swart was recently involved in overhauling the measles module from the WHO series "Immunological basis for immunization"

(<https://www.who.int/immunization/documents/ISBN9789241516655/en/>), and at organizing the exhibition "Vaccination Yes! / No?" At Natural History Museum Rotterdam.




Dr. Rosanne Hertzberger

Rosanne Hertzberger studied Life Science & Technology in Delft and Leiden. She obtained her PhD at the UvA at the Swammerdam Institute for Life Science under the supervision of Joost Teixeira de Mattos and Michiel Kleerebezem on oxygen metabolism of *Lactobacillus johnsonii*. She did a postdoc at Washington University St Louis School of Medicine in the lab of Dr. Amanda Lewis where she researched glycogen metabolism of vaginal bacteria. She is currently working as a guest researcher on the metabolism of vaginal lactic acid bacteria at VU University Amsterdam in the SysBiolab with Bas Teusink, Frank Bruggeman and Remco Kort.

In addition, she published the book *Ode to the E numbers* (2017) and *Het Grote Niets* (2019).

She writes a series on vaccination for *De Correspondent* and a weekly column in *NRC Handelsblad*.




Prof. dr. Helen McShane

Director of the Oxford NIHR Biomedical Research Centre; Professor of Vaccinology at Oxford University; Deputy Head (Translation and Personnel), Medical Sciences Division; and an Honorary Consultant Physician in infectious diseases.

Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997 She was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005 and 2010, she was awarded a Wellcome Senior Clinical Research Fellowship. She currently holds a Wellcome Trust Investigator Award. Helen was elected to be a fellow of the Academy of Medical Sciences in 2019.


Since 2001, Helen has lead a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. Current areas of focus include the development of controlled human mycobacterial challenge models, aerosol delivery of vaccines and immunomonitoring in clinical trials. She collaborates with several research groups across Africa in TB vaccine clinical trials.



Dr. Ir. Matthijs Jore

Department of Medical Microbiology Radboudumc
Postbus 9101
6500 HB Nijmegen
The Netherlands
Tel: +31 24 3610583
E-mail: Matthijs.Jore@radboudumc.nl

After completing the study of Molecular Sciences (WUR), in the group of Prof. dr. John van der Oost (WUR), PhD research on the CRISPR-Cas system in bacteria that was just discovered at the time and on which he obtained his PhD in 2010. Then, as a postdoc at Oxford University, he investigated how proteins in tick spit inhibit the human complement system. Using protein crystallography, he demonstrated how these proteins bind to human complement proteins, which also led to new insights into complement activation. Since 2016, he has been working as a researcher within the malaria research group at Radboud university medical center. He leads a research team working on the preclinical development of transmission blocking vaccines and antibodies. This includes the discovery of new vaccine candidates and human antibodies, and their in vitro and in vivo validation. He also contributes to the development of a vaccine and therapeutic antibody that will soon be tested in healthy volunteers. In 2019 he received a VIDI grant from NWO to investigate how malaria parasites can escape from the human complement system and how the complement system can be used to make more effective malaria vaccines.



Dr. Ir. Erwin Duizer

Erwin Duizer obtained his master degree in Cell Biology at the Agricultural University Wageningen in 1993 and his PhD after 4 years of research at TNO Food and Nutrition Research Institute in 1999 at the same university. In 1998 he started a postdoc position at the Research Laboratory for Infectious Diseases, at the national Institute for Public Health and the Environment (RIVM). At the RIVM he worked as senior scientist on viruses and foodsafety and viruses and hygiene while taking on several management tasks in the meantime. In 2015 he became Head of the National Polio Laboratory and WHO Specialized Reference Laboratory for Polio at the RIVM.

- 1998 –2002 Postdoc: Development of advanced human intestinal epithelial cell cultures for multiplication of enteropathogenic viruses & Molecular detection and viability screening of non-cultivable food borne viruses, Research Laboratory for Infectious Diseases, RIVM, Bilthoven.
- 2002-2015 Scientist working on “Enteric viruses and Foodsafety”, LIS, RIVM.
- 2004-2009 Assistant coordinator Food Borne Viruses in Europe (FBVE) network.
- 2005-2015 Member expert Network “Voedingscentrum”.
- Since 2006 Reviewer for several journals including the International Journal of Food Microbiology, Epidemiology and Infection, Journal of Virological Methods, Journal of Clinical Virology and Applied and Environmental Microbiology.
- 2007-2008 Projectleader gastro-enteric viruses, LIS, RIVM.
- 2008-2015 Head of section EntericViruses, IDS Virology, RIVM.
- Since 2013 board member SKML Virology section.
- Since 2015 Head of the National Polio Laboratory and WHO Specialized Laboratory for Polio, RIVM.



Dr. Nathalie Emma MacDermott

2C Westbrook road | London SE3 0NS | +447974818757 | nathalie.macdermott@kcl.ac.uk

Full GMC registration (6144308) | APLS & NLS certified

Languages: English and German (fluent), French (advanced), Italian (basic), BSL level 1

Nathalie MacDermott is a clinical doctor sub-specialising in paediatric infectious diseases in the NHS. She also has significant experience in medical response to disaster and epidemic situations in Africa and Asia. Nathalie's PhD research (Imperial College London) involved investigating genetic susceptibility to Ebola virus disease in West Africa, including the different phenotypes of disease and the dynamics of disease spread in communities. Her research interests are in paediatric global health, epidemic diseases and susceptibility to infectious disease from the perspective of host genetics.

Educational background

King's College London, London UK

- NIHR Academic Clinical Lecturer Jan 2020. Imperial College London, London UK
- Wellcome Clinical Research Training Fellow
PhD – 'Are there genetic determinants of clinical phenotype and disease outcome for Ebola virusdisease?' Mar 2015 – Jun 2019
- Wellcome Trust Global Health Clinical Training Fellow Aug 2012 – Aug 2013
Royal College of Paediatrics and Child Health, London UK
- Membership of Royal College of Paediatrics and Child Health May 2011 Fordham University, New York USA
- International Diploma in Humanitarian Assistance May - Jun 2010
Cardiff University, Cardiff UK/University of Wales College of Medicine, Cardiff UK
- Bachelor of Medicine & Bachelor of Surgery MBBCH (Honours) Sep 2000 – Jul 2006
- BSc Psychology and Medicine (1st Honours) Sep 2003 – Jul 2004

Experience

Postgraduate medical training – Paediatric infectious diseases subspecialty training

- London training programme Jan 2020-
- Wessex training programme Jun 2019 – Dec 2019
Postgraduate medical training – South Wales training programme
- Paediatric specialty training ST1-ST6 Aug 2009 – Sep 2014
- Foundation training, F1 & F2 Aug 2006 – Aug 2008
Samaritan's Purse International Relief – Disaster response
- South Sudan Ebola preparedness Oct – Nov 2018
- European Refugee Crisis, Macedonia/Greece Sep 2015
- Ebola epidemic response, Liberia Jul 2014 – Mar 2015
- Typhoon Haiyan Medical response, Philippines Dec 2013 – Jan 2014
- Cholera epidemic response, Haiti May 2011 – Jun 2011

Publications

Publications in peer reviewed journals: 5 Citations: 14

Books authored: 1

Imperial College London-University of Makeni Capacity Building 2017-2019

- Development of a training programme in development, design and delivery of degree courses for faculty from low income nations Imperial College London UK
- Course attended: 'An introduction to teaching for postdocs' 2016




VACCINOLOGY MASTERCLASS

- MSc in Healthcare and Design – lecturer 2016-2019
- Bsc in Reproductive and developmental sciences – lecturer 2016–2019
- Field team training Sierra Leone (PhD fieldwork) Nov–Dec 2016
- WHO ETAT training (MRC Gambia) May–June 2013 Samaritan’s Purse International Relief
- South Sudan Ebola Preparedness
Healthcare worker isolation facility training Oct-Nov 2018
- o Rapid response team infection prevention & control Oct-Nov 2018 training
- o World Food Program Master trainers - Ebola community Oct-Nov 2018 engagement training


Courses

- Advanced Paediatric Life Support (APLS) Mar 2019
Department for International Development/UK-MED
- UK Emergency Medical Teams pre-deployment training Dec 2018 Imperial College London
- Active Bystander and Persuasive Communication Nov 2018
- Genetic analysis of population based association studies Sep 2017
- MRC Centre for Medical Mycology/BPAIIG Sep 2017
- Medical Mycology from Bench to Bedside London School of Hygiene and Tropical Medicine
- Introductory course in epidemiology and medical statistics Jul 2016
- Equality, diversity and inclusion training Dec 2018
- Good clinical practice Mar 2016
- Informed consent in paediatric research Mar 2016 Elearning for Healthcare
- Safeguarding children levels 1-3 Apr 2014 Awards Imperial College London
- Student Award for Outstanding Achievement 2016 May 2017. Her Majesty’s Government (UK)
- Ebola Medal for Service in West Africa Oct 2015 Wales Postgraduate Medical Deanery
- Paediatric trainee contribution to wider community 2015 May 2015 Cardiff University
- Achievement of Clinical Excellence in Medicine Jul 2006



Professor Harish Nair

Harish Nair is Chair of Paediatric Infectious Diseases and Global Health at the Edinburgh Medical School, University of Edinburgh. He is trained in clinical Paediatrics and Epidemiology. He leads the Respiratory Viral Epidemiology Research Group at the University of Edinburgh. He has led several large collaborative projects on global child health and infectious diseases and has raised around £48 million in research grant income and has published over 100 articles, 27 of them in high impact journals. He currently leads (and is the coordinator of) the REspiratory Syncytial virus Consortium in EUrope (RESCEU) (<http://resc-eu.org/>). He leads the RSV Global Epidemiology Network (RSV GEN) which has developed the previous and current paediatric global RSV morbidity and mortality estimates. His current projects include work on child pneumonia, RSV, influenza and other infectious diseases like pneumococcus, meningococcus and Clostridium difficile. Prof Nair is an adviser to the World Health Organisation and Bill and Melinda Gates Foundation; and a founding board member of ResViNET. He is a Fellow of the Royal College of Physicians of Edinburgh and Faculty of Public Health (UK). He is also the Regional Editor of the Journal of Global Health and member of several international scientific advisory boards for ongoing studies on RSV. He was recently awarded the Principal's Medal for Exceptional Service by the University of Edinburgh and the Hind Rattan (Jewel of India) award for his contribution to global public health.



Prof. dr. Jaap T. van Dissel


Jaap van Dissel (1957) is directeur van het Centrum Infectieziektebestrijding (Cib Centrum Infectieziektebestrijding) van het Rijksinstituut voor Volksgezondheid en Milieu (RIVM Rijksinstituut voor Volksgezondheid en Milieu). Daarnaast is hij hoogleraar Interne Geneeskunde, in het bijzonder de infectieziekten, bij het Leids Universitair Medisch Centrum (LUMC Leids Universitair Medisch Centrum). Voor zijn komst naar het RIVM Rijksinstituut voor Volksgezondheid en Milieu was Jaap van Dissel hoofd van de afdeling Infectieziekten bij het LUMC Leids Universitair Medisch Centrum . Daarnaast was hij hoofdopleider Interne Geneeskunde en voorzitter van het Centrum voor Infectieziekten. Hij wisselde zijn carrière bij het LUMC af met een onderzoeksperiode bij het Duke University Medical Center in Durham en het Cold Spring Harbor Laboratory in de Verenigde Staten.

Van Dissel begeleidde meer dan 25 promovendi en publiceerde meer dan 280 wetenschappelijke publicaties, grotendeels over infectieziekten. Daarnaast schreef hij mee aan ruim 75 opleidingsmodules en boeken over infectieziekten.

Naast zijn baan bij het RIVM werkt Jaap van Dissel één dag per week bij het LUMC, waar hij een polikliniek voor afweerstoornissen leidt en diverse onderzoeksprojecten en promovendi begeleidt.


Expertise:

- Afweerstoornissen
- Klinische infectieziekten
- Antibiotica en antibioticabeleid
- Cellulaire immuniteit en intracellulaire infecties



Dr. Bart. L. Haagmans

Bart Haagmans (1963) is a virologist, working at the Viroscience department of the Erasmus Medical Center in Rotterdam. He studied at Utrecht University and obtained his doctorate from the same university. His interest is the pathogenesis of viral infections, including SARS, MERS and the new coronavirus. The study includes the characterization of viral variants and the serological response generated in the different host species. In addition, the genomes of many other new viruses and their variants have been characterized by complete genome analysis. In recent years, for example, we have characterized the genome of the MERS coronavirus, identified the receptor and contributed to the identification of the dromedary camel as the reservoir species. We have tested a vaccine candidate that reduces the transmission of MERS-CoV by vaccinating dromedary camels. He is currently working on further characterizing the SARS-CoV-2 virus, developing molecular and serological tests and vaccine candidates for this virus.



PRAKTISCHE INFORMATIE

Datum: 1 en 2 oktober 2020

Ontvangst 1 oktober vanaf 8.30 uur!

Locatie: Hotel van der Valk, Veluwezoom 45, 1327 AK Almere

tel: 036-8000800.

De organisatie is beide dagen bereikbaar op 06-214243899



Route:

Vanuit de richting Haarlem/Amsterdam (A1)

Vanaf de A1 richting Amersfoort neem je de A6 richting Almere. Op de A6 neem je afslag 5 (Almere Stad). Aan het eind van de afslag ga je linksaf richting Almere Stad (S103 Veluwedreef). Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vind je Hotel Almere.

Vanuit de richting Utrecht (A27)

Vanaf de A27 richting Hilversum/Huizen neem je afslag 36 richting Almere Stad. Aan het eind van de afslag ga je linksaf richting Almere Haven/Almere Stad (N305). Vlak voor Almere rijd je onder het viaduct van de snelweg A6 door, nog steeds richting Almere Stad. De weg heet nu Veluwedreef. Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vindt je Hotel Almere.

Vanuit de richting Lelystad (A6)

Vanaf de A6 richting Almere neem je afslag 5 (Almere Stad). Aan het eind van de afslag ga je bij het verkeerslicht linksaf richting Almere Stad (S103 Veluwedreef). Bij het 1e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vind je Hotel Almere.

Vanuit de richting Amersfoort binnendoor (A28)


Vanaf de A28 richting Zwolle neem je de afslag Nijkerk. Aan het eind van de afslag ga je bij de verkeerslichten linksaf richting Almere (N301). Bij de eerste en tweede rotonde neem je de 2e afslag, dus rechtdoor. Bij de derde rotonde ga je linksaf richting Almere (N305). Vlak voor Almere rijd je onder het viaduct van de snelweg A6 door richting Almere Stad. De weg heet nu Veluwedreef. Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vindt je Hotel Almere.

Vanuit de richting Apeldoorn / Amersfoort (A1)

Vanaf de A1 richting Amersfoort heb je twee mogelijkheden:

* Vervolg de route via de A28 en dan binnendoor (zie hierboven)

* Vervolg de route over de A1 verder richting Amsterdam. Neem bij Hilversum de afslag naar de A27 richting Almere/Huizen. Vervolg verder de route vanuit de richting Utrecht (zie boven).



Vanuit de richting Zwolle (A28)

Vanaf de A28 richting Amersfoort heb je twee mogelijkheden:

* Via Lelystad: zie route vanuit de richting Lelystad.

* Vanaf de A28 richting Amersfoort/Utrecht neem je de afslag Harderwijk. Je vervolgt uw route via de N302 richting Lelystad. Daarna vervolg je de route via de N305 richting Almere. Vlak voor Almere rijd je onder het viaduct (snelweg A6) door richting Almere Stad. De weg heet nu Veluwedreef. Bij het 2e verkeerslicht sla je linksaf de Veluwezoom op. Aan je rechterhand vind je Hotel Almere.

Met het openbaar vervoer:

Hotel Almere is uitstekend met het openbaar vervoer te bereiken. Treinstations Almere Parkwijk en Almere Centrum zijn per auto slechts enkele minuten van het hotel verwijderd. Vanaf deze stations kan je per bus of taxi naar het hotel reizen. Vanaf zowel Station Almere Parkwijk als Almere Centrum kan je bus M5 nemen en uitstappen bij bushalte Walt Disneyplantsoen. Vanaf deze halte is het ongeveer 10 minuten lopen naar Hotel Almere.

Kosten: Cursusdeelnemers betalen € 295,- per persoon.

Deze bedragen zijn inclusief koffie, thee, lunches en diner. Alle prijzen zijn per persoon.

Optie online deelname: De 2-daagse nascholing wordt volledig live online gestreamd. Geaccrediteerde online deelname met chatfunctie is mogelijk. De kosten hiervan bedragen € 230,- per persoon.

Hotelovernachting:

Overnachten bij Hotel Van der Valk is mogelijk tegen een gereduceerd tarief van 120 euro per kamer. Je kunt bij het inschrijven aangeven of je van deze mogelijkheid gebruik wilt maken. Wij hebben 30 kamers in optie genomen en de optie verloopt in september. Wacht daarom niet te lang.

Lunch en diner: Wij houden graag rekening met dieetrestricties.

Wil je deze uiterlijk 23 september doorgeven aan de organisatie van de twee-daagse: Info@gerhardbruggink.nl.

Mailing en adressering: Graag houden wij je op de hoogte van voor jou interessante bijeenkomsten en diensten. Je bent daartoe opgenomen in ons adressenbestand. Dit bestand zal nooit ter beschikking gesteld worden aan derden.



VACCINOLOGY MASTERCLASS

SPONSOR INFORMATIE

De Stichting Vaccinology Masterclass wordt financieel ondersteund door GlaxoSmithKline, Pfizer, Sanofi Pasteur en MSD. Deze bedrijven hebben op geen enkele manier invloed op de inhoud van het programma. De Stichting en de Faculty zijn de bedrijven zeer erkentelijk voor hun ondersteuning.



GlaxoSmithKline, Huis ter Heideweg 62, 3705 LZ Zeist



Pfizer, Rivium Westlaan 142, 2909 LD Capelle a/d IJssel



Sanofi Pasteur, Paasheuvelweg 25, 1105 BP Amsterdam



MSD, Waarderweg 39, 2031 BN Haarlem

